Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...

If approved ... for patients with T1D. The FDA is reviewing the BLA for datopotamab deruxtecan (Dato-DXd), a specifically engineered TROP2-directed DXd antibody drug conjugate, for the treatment ...

Drugs approved for FDA Fast Track may also be eligible for Accelerated ... therapies are urgently required in areas with limited or non-existent treatment options. Note: Drug developers are ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...